Search alternatives:
ng decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
ng decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
-
81
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
82
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
ngLVA degradation kinetics.
Published 2022“…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
Flow chart of the study procedures.
Published 2023“…In the multivariable analysis, higher age (predicted monthly RPR relative change on the log2 scale 0.23/10 years [95% confidence interval [CI], 0.090–0.37]), history of syphilis (0.36 [95% CI, 0.07–0.65]), and a lower ratio of RPR at treatment initiation/diagnosis (−0.52/every 10-fold increase [95% CI, −0.81 to −0.22]) were associated with a slower RPR decrease after treatment.…”